Injectable HIV treatment for people new to therapy
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study tests a new shot (called VH4011499) that may help control HIV. It is given together with another shot, cabotegravir, so you might not need to take daily pills. The study is for people who have never treated their HIV before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have never taken HIV treatment before.
- Your CD4 count must be 200 or higher.
- Your viral load must be between 1,000 and 100,000 copies per milliliter.
- You must meet weight requirements (at least 110 lbs if you were born male, or 99 lbs if you were born female).
- You must not have hepatitis B or C infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.